LALPATHLAB

Dr. Lal Path Labs Balance Sheet

₹1,950.50-0.70%
Market cap
₹32,569 crore
P/E
60.1
P/B
12.99
ROE
21.6%
Dividend yield
0.46%

As of Mar 2022, Dr. Lal Path Labs had total assets of ₹13,700 crore and borrowings of ₹1,200 crore, against shareholders' equity of ₹9,000 crore — a debt-to-equity ratio of 0.13. Borrowings rose 186.05% from Mar 2023.

Dr. Lal Path Labs balance sheet

As at each financial year end, newest first. H1 = half-year.

Dr. Lal Path Labs balance sheet (₹ crore)
ItemMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital50083.3783.4883.59168
Reserves8,5001,3511,5771,8602,153
Borrowings1,200420247157199
Other liabilities3,500267324353406
Total liabilities13,7002,3862,4562,7173,146
Fixed assets6,500405348343490
Capital work in progress400100100100100
Investments2,500477491543629
Other assets4,300716737815944
Total assets13,7002,3862,4562,7173,146

Balance sheet ratios

Debt to equity
0.13

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Dr. Lal Path Labs balance sheet — frequently asked questions

What is the total debt of Dr. Lal Path Labs?

Dr. Lal Path Labs reported borrowings of ₹1,200 crore as of Mar 2022, compared with ₹420 crore as of Mar 2023.

What is Dr. Lal Path Labs' debt-to-equity ratio?

Based on the Mar 2022 balance sheet, Dr. Lal Path Labs' debt-to-equity ratio is 0.13 — borrowings of ₹1,200 crore against equity capital and reserves of ₹9,000 crore.

What are Dr. Lal Path Labs' total assets?

Dr. Lal Path Labs' total assets were ₹13,700 crore as of Mar 2022, including fixed assets of ₹6,500 crore and investments of ₹2,500 crore.

Same Data For Peers

Trade Dr. Lal Path Labs With ATS

Track LALPATHLAB live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.